The 'Dispatched' Week in Review' Podcast - 31 July

This is a preview of subscriber content

Subscribe now to continue reading.

The events in the US this week surrounding a former public health leader raise some important questions in Australia about the accountability of 'independent experts'. Why we can't afford to muck up the AI opportunity as new evidence on its use emerges globally. Ongoing debate over access to medicines and the impact of global pricing. …

Subscribe now to continue reading.

The 'Dispatched' Week in Review' Podcast - 31 July

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Opportunity #4 - Scope creep demands stronger checks and balances

Departmental restructure formally splits medicines financing from pharmacy services

CSL absorbs loss in reset year as investors back its plasma-led recovery

Opportunity #2 - AI can democratise HTA and the negotiations must not squander it

New Stories

Advent moves to acquire majority stake in NZCR Group

Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma

Biogen bolsters leadership ranks as it sharpens focus on patient access and innovation

Opportunity #5 - From the hardest thing to secure to the easiest thing to get right

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

New Zealand researchers honoured for work tackling superbugs and blood cancer

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm

Sign In

The 'Dispatched' Week in Review' Podcast - 31 July

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Opportunity #4 - Scope creep demands stronger checks and balances

Departmental restructure formally splits medicines financing from pharmacy services

CSL absorbs loss in reset year as investors back its plasma-led recovery

Opportunity #2 - AI can democratise HTA and the negotiations must not squander it

Follow Us

New Stories

Advent moves to acquire majority stake in NZCR Group

Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma

Biogen bolsters leadership ranks as it sharpens focus on patient access and innovation

Opportunity #5 - From the hardest thing to secure to the easiest thing to get right

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

New Zealand researchers honoured for work tackling superbugs and blood cancer

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm